We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TNET:NYSETriNet Group, Inc. Analysis

Data as of 2026-05-27 - not real-time

$43.62

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

TriNet is trading around $43.6, well below its DCF‑derived fair value of roughly $59 and far under the industry’s average PE of 30, signaling a clear undervaluation. The company just delivered a Q1 EPS beat and reaffirmed its guidance, sparking a 10% price rally and underscoring momentum from recent earnings. Dividend yield sits at 2.73% with a modest 33% payout ratio, suggesting a sustainable income stream.
Technical indicators are mixed: the 20‑day SMA (≈42.35) sits just below the current price, MACD remains bullish, and RSI at 58 indicates room before overbought conditions. Support around $38.36 and resistance near $46.38 frame a neutral trend, while volatility is high (≈45% 30‑day) but beta is low (≈0.65), tempering market‑wide risk. Balance‑sheet pressure is notable, with debt‑to‑equity exceeding 1,100% and ROE only about 2.2%.
Given the valuation upside of roughly 16% and a sustainable dividend, the short‑ to medium‑term outlook leans toward buying, but long‑term exposure should be moderated due to leverage and modest profitability.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Recent EPS beat and reaffirmed guidance
  • Bullish MACD and supportive dividend yield
  • Price near short‑term support with neutral trend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to DCF fair value and industry PE
  • Sustainable 2.73% dividend providing income
  • Upside potential of ~16% based on valuation gap

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage (debt‑to‑equity >1,100%) raising balance‑sheet risk
  • Low ROE and modest profitability
  • Stable cash flow supporting dividend but limiting growth

Key Metrics & Analysis

Financial Health

Revenue Growth-4.90%
Profit Margin3.26%
P/E Ratio12.9
ROE217.81%
ROA4.19%
Debt/Equity1139.76
P/B Ratio38.3
Op. Cash Flow$357.0M
Free Cash Flow$252.3M
Industry P/E30.1

Technical Analysis

TrendNeutral
RSI58.7
Support$38.36
Resistance$46.38
MA 20$42.35
MA 50$39.79
MA 200$53.74
MACDBullish
VolumeStable
Fear & Greed Index92.34

Valuation

Fair Value$58.96
Target Price$50.60
Upside/Downside16.00%
GradeUndervalued
TypeValue
Dividend Yield2.73%

Risk Assessment

Beta0.65
Volatility45.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.